Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial (PRNewswire)

Eli Lilly’s Oral GLP-1 Drug Orforglipron Shows Strong Results in Phase 3 Trial

Eli Lilly’s investigational oral GLP-1 receptor agonist, orforglipron, met key endpoints in its Phase 3 ACHIEVE-1 trial for adults with type 2 diabetes. Unlike injectable GLP-1 drugs, orforglipron is a once-daily pill with no food or water restrictions.

Key Highlights:

• A1C reduction: 1.3% to 1.6% (vs. 0.1% for placebo)
  
• Weight loss: Up to 16.0 lbs (7.9% body weight) at the highest dose
  
• Safety profile: Consistent with injectable GLP-1s; main side effects were mild-to-moderate GI issues like nausea and diarrhea
• Global rollout: Lilly expects no supply constraints if approved